Biovica International
15.9.2021 08:21:46 CEST | ACCESS Newswire | Press release
UPPSALA, SE / ACCESSWIRE / September 15, 2021 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)
Biovica, active in cancer diagnostics, today announces that DiviTum®TKa results from an analysis of samples from the large SWOG S0226 study have been published in the highly ranked peer-reviewed scientific journal Clinical Cancer Research, published by the American Association for Cancer Research (AACR). The strong results support using DiviTum®TKa as a tool to monitor disease progression with endocrine therapy in women with hormone receptor positive metastatic breast cancer.
"SWOG researchers have demonstrated that a blood serum test can identify which of these patients have slow-growing disease that might be controlled with a simple aromatase inhibitor pill alone," said co-author of the paper, Dr. Lajos Pusztai, MD, PhD, Yale University Cancer Center.
"We are very proud to see the strong DiviTum®TKa results being published in Clinical Cancer Research. This highly reputable scientific journal by AACR focuses on innovative clinical and translational research bridging the laboratory and the clinic. The publication is a great recognition for DiviTumTKa and an important step to establishing the test as a standard tool for monitoring treatment of metastatic breast cancer to the benefit of patients and payers," said Anders Rylander, CEO of Biovica.
As previously announced, results demonstrate that patients with low TKa levels (using a predefined cut-off) before treatment initiation will do significantly better than patients expressing high levels of TKa. Progression free survival (PFS) was 17.3 vs 11.2 months and overall survival (OS) was 58 vs 30 months, respectively. In addition, similar results were observed during treatment, where patients with low TKa showed significantly longer PFS and OS. Furthermore, results support the potential clinical use of DiviTum®TKa to identify low-TKa patients as best suited for endocrine monotherapy, whereas those with elevated TKa values appear to benefit from combination therapies.
The analysis measured thymidine kinase activity (TKa) levels in 1,726 serum samples from more than 400 patients in SWOG S0226 and is the largest study to evaluate DiviTum®TKa for prognostic and serial monitoring of metastatic breast cancer. The study constitutes the foundation for the clinical validation of DiviTum®TKa in Biovica's 510(k)-application to the FDA. DiviTum®TKa is 510(k) pending. Not available for sale in the United States.
Link to study: Clinical Cancer Research
Contact
Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se , +46 8 528 00 399. For more information please visit: www.biovica.com .
SOURCE: Biovica International
View source version on accesswire.com:
https://www.accesswire.com/664165/DiviTumRTKa-Results-from-SWOG-Study-Published-in-Clinical-Cancer-Research
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Polaris Renewable Energy Announces Q1 2026 Investor Call Details8.4.2026 01:35:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / April 7, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") is pleased to announce it will be holding its Earnings Conference Call and Webcast to report its Q1 2026 Earnings Results on Thursday, May 7th, 2026, at 10:00 am EST. To listen to the call, please dial Toll Free 1888-506-0062 or International Toll-Free Number 973-528-0011 entry code 939001. or URL: https://www.webcaster5.com/Webcast/Page/2773/53516 A digital recording of the earnings call will be available for replay two hours after the call's completion. Replay Call Information: Toronto: 1 877-481-4010, Passcode: 53516 International (toll-free): 1 919-882-2331, Passcode: 53516 Encore Replay Expiration Date: May 21, 2026 About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America and the Caribbean. We are a high-performing and f
Formerra Announces Global Price Increase7.4.2026 22:00:00 CEST | Press release
CLEVELAND, OH / ACCESS Newswire / April 7, 2026 / Formerra, a leading distributor of performance materials, today announced a global price increase of $0.02 / lb on all products. The increase addresses higher operating costs related to rising material costs, exacerbated by the conflict in the Middle East. The adjustment goes into effect on April 15, 2026, or as contracts otherwise allow. Formerra remains committed to maintaining ample inventory levels and the service excellence our valued customers deserve. Customers should contact their Formerra representative for additional information. About Formerra Formerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce c
Karbon-X Expands Enterprise Climate Platform Through Strategic Partnership with carbon-connect AG7.4.2026 15:00:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / April 7, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions provider operating across compliance and voluntary carbon markets, today announced a strategic collaboration with carbon-connect AG ("carbon-connect"), a Switzerland-based greenhouse gas (GHG) accounting and sustainability advisory firm. The collaboration marks a continued expansion of Karbon-X's enterprise climate platform, strengthening its carbon measurement, decarbonization advisory, and ongoing monitoring capabilities for corporate and regulated clients. Karbon-X will lead commercial engagement and client integration, incorporating carbon-connect's technical expertise into its end-to-end climate solutions framework. The enhanced service offering includes: Full Scope 1,2, and 3 emissions accounting Emissions abatement planning and implementation Country-specific compliance, ESG, and sustainability reporting Product carbon quantificatio
U.S. Polo Assn. and ESPN Champion the Iconic USPA Gold Cup at the USPA National Polo Center, Hosted by Legendary Commentator Chris Fowler7.4.2026 13:00:00 CEST | Press release
USPA Gold Cup Finals to Air on ESPN and Global Polo Platforms WEST PALM BEACH, FL / ACCESS Newswire / April 7, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), proudly supported the USPA Gold Cup® at the USPA National Polo Center (NPC) in Wellington, Florida on April 5, 2026, Easter Sunday in front of a record crowd at the U.S. Polo Assn. Stadium Field.1. 2026 USPA Gold Cup Winners, Team Pilot (#1 Curtis Pilot - 0, #2 Mackenzie Weisz - 6, #3 Lorenzo Chavanne - 7, #4 Camilo ‘Jeta' Castagnola - 10) on stage with iconic trophy at the USPA National Polo Center - Wellington, Florida 2. Cousins, but rivals on the field - Pilot's Camilo ‘Jeta' Castagnola and La Dolfina Scone's Poroto Cambiaso battle for the ball at the 2026 USPA Gold Cup Final Photo Credit: Augustina Fonda As the second most prestigious tournament in the United States and a critical leg of the Gauntlet of Polo®, the USPA Gold Cup brings together the sport's top players and elite
Datavault AI CEO Nathaniel T. Bradley to Deliver Flagship Keynotes on Breakthrough RWA Tokenization at CONV3RGENCE London and AssetRush × Zurich 20266.4.2026 15:15:00 CEST | Press release
Building Global Momentum Ahead of Upcoming XRP Tokyo Event PHILADELPHIA, PA / ACCESS Newswire / April 6, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a leader in AI-driven data valuation, monetization, credentialing, digital engagement, and real-world asset (RWA) tokenization technologies, today announced that CEO Nathaniel T. Bradley will deliver high-impact keynote presentations at two premier European financial innovation events this spring. On April 22, 2026, Bradley will headline CONV3RGENCE London & The Digital Commonwealth Awards 2026 at the historic Mansion House in London as Flagship Partner. One month later, on May 21, 2026, he will take center stage as Main Strategic Partner at AssetRush × Zurich 2026, GenTwo's flagship "festival of financial innovation" at Kaufleuten Zurich, delivering the opening speech and a major talk on the future of tokenized assets. These back-to-back European keynotes build on Bradley's upcoming presentation at XRP Tokyo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom